Pluri Inc. Revenue from Contract with Customer, Including Assessed Tax
Pluri Inc. (PLUR) reported Revenue from Contract with Customer, Including Assessed Tax of $1.34 million for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-17.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2025-09-17
- Pluri Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-03-31 was $0.00.
- Pluri Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-12-31 was $0.00.
- Pluri Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-09-30 was $250.00K.
- Pluri Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $1.34M, a 309.82% increase from fiscal 2024.
- Pluri Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $326.00K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-06-30 | $1.34M 10-K · filed 2025-09-17 | |||
| 2024-06-30 | $326.00K 10-K · filed 2025-09-17 | |||
| 2019-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-06 | $0.00 derived: sum of 2 quarters · filed 2019-05-06 | $250.00K 10-Q · filed 2019-05-06 | |
| 2018-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-06 | $250.00K 10-Q · filed 2019-02-06 | ||
| 2018-09-30 | $250.00K 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |